Sun-Mi Park, Mithat Gönen, Ly Vu, Gerard Minuesa, Patrick Tivnan, Trevor S Barlowe, James Taggart, Yuheng Lu, Raquel P Deering, Nir Hacohen, Maria E Figueroa, Elisabeth Paietta, Hugo F Fernandez, Martin S Tallman, Ari Melnick, Ross Levine, Christina Leslie, Christopher J Lengner, Michael G Kharas
Leukemia stem cells (LSCs) are found in most aggressive myeloid diseases and contribute to therapeutic resistance. Leukemia cells exhibit a dysregulated developmental program as the result of genetic and epigenetic alterations. Overexpression of the RNA-binding protein Musashi2 (MSI2) has been previously shown to predict poor survival in leukemia. Here, we demonstrated that conditional deletion of Msi2 in the hematopoietic compartment results in delayed leukemogenesis, reduced disease burden, and a loss of LSC function in a murine leukemia model...
March 2, 2015: Journal of Clinical Investigation